Susquehanna Portfolio Strategies’s BioMarin Pharmaceuticals BMRN Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.8M	Sell	31,809 -21,610	-40%	-$1.26M	0.03%	515
2025 Q4	$3.17M	Sell	53,419 -179,028	-77%	-$9.75M	0.05%	403
2025 Q3	$12.6M	Buy	232,447 +112,128	+93%	+$6.41M	0.2%	142
2025 Q2	$6.61M	Buy	120,319 +101,451	+538%	+$5.97M	0.14%	191
2025 Q1	$1.33M	Buy	+18,868	New	+$1.27M	0.57%	40
2024 Q2	–	Sell	-39,949	Closed	-$3.49M	–	547
2024 Q1	$3.49M	Sell	39,949 -162,736	-80%	-$14.6M	0.08%	258
2023 Q4	$19.5M	Buy	+202,685	New	+$17.9M	0.35%	79

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna Portfolio Strategies's BMRN Position: Q1 2026 in Review

Susquehanna Portfolio Strategies reduced its BioMarin Pharmaceuticals (BMRN) stake by 40% in Q1 2026, selling an estimated $1.26M and leaving 31,809 shares worth $1.8M. The position accounts for 0.03% of the portfolio, ranked #515.

Susquehanna Portfolio Strategies first reported a position in BMRN in Q4 2023 and has held it in 7 quarters since. The position peaked at $19.5M in Q4 2023. 555 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Susquehanna Portfolio Strategies held 31,809 shares of BioMarin Pharmaceuticals worth $1.8M as of Q1 2026.
Susquehanna Portfolio Strategies sold 21,610 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $1.26M.
BioMarin Pharmaceuticals made up 0.03% of Susquehanna Portfolio Strategies's portfolio in Q1 2026, its #515 holding.
Susquehanna Portfolio Strategies first reported a position in BioMarin Pharmaceuticals in Q4 2023 and has held it in 7 quarters since.
Susquehanna Portfolio Strategies's BioMarin Pharmaceuticals position peaked at $19.5M in Q4 2023.
555 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q1 2026, filed 15 May 2026.